We are developing safe and effective treatments to improve and extend the lives of patients with Friedreich's Ataxia, a deadly inherited genetic neurological disease.
Ittero Therapeutics is seeking an initial seed investment to manufacture rationally designed novel patent-protected molecules - known to have sufficient drug-like properties and address disease at the transcription level - and to test these in the patient-derived cellular assay in collaboration with an academic researcher. Subsequent to a demonstration of adequate in-vitro data, Ittero plans to perform in-vivo studies with the same lab and investigator to rapidly advance a molecule towards IND filing and clinical use initially in patients with rapid onset of the disease characterized by high repeat expansion numbers.
The funds will be used mostly for molecule synthesis by a world-class manufacturer (quote ready) as well as paying for consultants, corporate attorney fees, and patent filing costs.
Ready to Ask For Funding for your company?
Post a Funding Request